Amgen's Repatha Pricing Deal With Harvard Pilgrim Hinges On Results, Utilization
This article was originally published in The Pink Sheet Daily
Additional discounts kick in if patients don't achieve same LDL cholesterol reduction seen in clinical trials and if utilization is excessive.
You may also be interested in...
Harvard Pilgrim Chief Medical Officer Michael Sherman said the full warranty behind the agreement is the right kind of deal to balance access and cost.
Amgen seeking additional outcomes-based contracts in rheumatoid arthritis through collaboration with Inovalon/Avalere.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.